388109-44-2Relevant academic research and scientific papers
CC chemokine receptor-3 (CCR3) antagonists: Improving the selectivity of DPC168 by reducing central ring lipophilicity
Pruitt, James R.,Batt, Douglas G.,Wacker, Dean A.,Bostrom, Lori L.,Booker, Shon K.,McLaughlin, Erin,Houghton, Gregory C.,Varnes, Jeffrey G.,Christ, David D.,Covington, Maryanne,Das, Anuk M.,Davies, Paul,Graden, Danielle,Kariv, Ilona,Orlovsky, Yevgeniya,Stowell, Nicole C.,Vaddi, Krishna G.,Wadman, Eric A.,Welch, Patricia K.,Yeleswaram, Swamy,Solomon, Kimberly A.,Newton, Robert C.,Decicco, Carl P.,Carter, Percy H.,Ko, Soo S.
, p. 2992 - 2997 (2008/02/05)
DPC168, a benzylpiperidine-substituted aryl urea CCR3 antagonist evaluated in clinical trials, was a relatively potent inhibitor of the 2D6 isoform of cytochrome P-450 (CYP2D6). Replacement of the cyclohexyl central ring with saturated heterocycles provid
N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity
-
, (2008/06/13)
The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.
